Compare IMPP & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMPP | NKTX |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.3M | 133.5M |
| IPO Year | N/A | 2020 |
| Metric | IMPP | NKTX |
|---|---|---|
| Price | $4.12 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.50 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 1.2M | 650.8K |
| Earning Date | 12-11-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $136,071,654.00 | N/A |
| Revenue This Year | $9.69 | N/A |
| Revenue Next Year | $51.33 | N/A |
| P/E Ratio | $4.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.12 | $1.31 |
| 52 Week High | $6.57 | $2.74 |
| Indicator | IMPP | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.19 | 45.33 |
| Support Level | $4.04 | $1.81 |
| Resistance Level | $4.49 | $1.90 |
| Average True Range (ATR) | 0.38 | 0.07 |
| MACD | -0.12 | 0.02 |
| Stochastic Oscillator | 4.05 | 52.50 |
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.